Robust Investment in Greater Philadelphia Region’s Cell and Gene Therapy Sector Continued in the First Quarter of 2021 PHILADELPHIA (April 8, 2021) – The robust venture capital funding the Greater [….]
The Discovery Labs’ 2.4 million square foot site in King of Prussia, PA provides all the necessary ingredients to accelerate speed to market for cell and gene therapy innovators. The Center for Breakthrough Medicines is a cell and gene therapy contract development and manufacturing organization (CDMO) for plasmid DNA, viral vectors, and cellular therapy products and is located on-site.
As some are now calling it, the greater Philadelphia region, or ‘Cellecon Valley, is garnering a lot of attention these days as a rapidly emerging Biopharma cluster, earning a defining spot among the top 10 clusters in the US.
Life Science Cares Philadelphia launched Project Onramp Philadelphia, a program aimed at connecting economically disadvantaged college students with paid summer internships at life science companies based in the area.
Philadelphia, the birthplace of cell and gene therapy, is home to a number of companies focused on developing multiple treatment options for rare diseases, those that affect less than 200,000 people in the United States.
Philadelphia-based CARISMA Therapeutics Inc. secured $47 million in a Series B financing round that will be used to advance the development of the company’s novel chimeric antigen receptor macrophages (CAR-M) immunotherapies.
The Philadelphia life sciences ecosystem has contributed to the improvement of countless lives through the development of innovative therapies. Over the past year, the more than 50,000 employees in this sector have been able to give back even more to their community through Life Sciences Cares Philadelphia.
Tia Lyles-Williams, the founder & CEO of LucasPye BIO (LPB) and HelaPlex, is on a mission to lower development and manufacturing costs for emerging life science companies while bringing greater diversity to the life science industry.
Philadelphia is not just the city of brotherly love. It is one of the nation’s top biopharma hubs and the birthplace of cell and gene therapy. Within the next few years, the role of life sciences companies and institutions that call the city home is expected to grow at an accelerated rate, further cementing the city’s place as a key biopharma ecosystem.
ARON STAROSTA, PH.D. JOINS UNIVERSITY CITY SCIENCE CENTER AS VICE PRESIDENT, COMMERCIALIZATION AND NEW VENTURES
